Annexon pairs $213.4m cash with up to $200m credit facility ahead of tanruprubart filing

Annexon reported cash of $213.4 million in its third-quarter 2026 update on 9 November. It said this funds operations into 2028. It also disclosed a credit facility of up to $200 million with Oxford Finance. The update does not say how much of that facility is drawn or how the money would be allocated.

The financing sits alongside two regulatory and clinical events the company expects in the coming weeks. Annexon plans to submit a Biologics License Application (BLA) in the fourth quarter of 2026 for tanruprubart, its treatment for Guillain-Barré syndrome. The same drug is already under review by the European Medicines Agency. No outcome date for the European review has been given, and the summary of the update gives neither an exact US submission date nor details of the data package.

Annexon also expects an independent Data Monitoring Committee to assess the Month 15 primary endpoint of ARCHER II in the fourth quarter. ARCHER II is a Phase 3 trial of vonaprument in geographic atrophy, an eye disease. The update does not say what form the assessment will take or when results might be shared.

For context, a BLA submission is the formal request for US approval of a biologic. It is followed by a review period at the Food and Drug Administration, so any US launch would come after the filing. The update contains no pricing, revenue or launch-timing information for tanruprubart.